Replies to post #114274 on Biotech Values

[poorgradstudent]

Device-makers are having a terrible time getting new products that might give them pricing power approved by the FDA. Health reform adds a new 2.3% excise tax on many of the companies (though not lab equipment). And there’s demographic evidence that the number of baby boomers whose creaky knees and bad hearts fueled a decade of explosive growth for many medical manufacturers has peaked. Many of those patients are close to or already becoming cost-controlled Medicare patients.

?

That sounds very unrelated to what BEC sells.